All lobbying filings
Orchard Therapeutics North America
Orchard Therapeutics North America filed a Q1 amendment for Orchard Therapeutics North America on April 29, 2026.
Lobbying for Orchard Therapeutics North America · Health
Filing · LD-2 quarterly report
Q1 amendment
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 29, 2026
Expenses
$470,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Massachusetts
Government bodies contacted
5
Lobbying activity
2
H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's
Accelerating Kids' Access to Care Act and Pediatric Priority Review Voucher (Give Kids a Chance Act) FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including HRSA Appropriations & Fundings; RUSP Conditions
Bills named in this filing
1